# Hervé Dombret

Source: https://onco.cc/people/herve-dombret/  
OnCo record `herve-dombret` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy.

## Summary

Hervé Dombret is a haematologist at Hôpital Saint-Louis in Paris and a long-standing leader of the French ALFA and GRAALL leukaemia cooperative groups. He was first author of the 2015 Blood report of AZA-AML-001, the international phase 3 trial of azacitidine against conventional care regimens in older patients with newly diagnosed AML and more than 30 percent marrow blasts, which supported azacitidine's use in this population.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: leukaemia; trialist
- Role: Haematologist, Hôpital Saint-Louis (AP-HP), Paris
- Specialisms: Acute myeloid leukaemia; Acute lymphoblastic leukaemia; Cooperative-group trials

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute myeloid leukaemia in older or unfit patients](https://onco.cc/cancers/aml-older-unfit/)
- institutions: [Cancer Institute AP-HP Nord, Université Paris Cité](https://onco.cc/institutions/aphp-nord-cancer-institute/)
- key papers: [AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts](https://onco.cc/key-papers/paper-aza-aml-001-dombret-blood-2015/)

---
JSON: https://onco.cc/api/v1/entities/herve-dombret.json